/Incyte%20Corp_%20logo%20and%20bar%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.
Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.
What makes analysts so bullish about these three names from the sector?
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.
/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.
/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader...
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.